A new fund named in honour of a young Northland woman who died from a devastating lung disease at 24 will help support families affected by bronchiectasis. The Asthma and Respiratory Foundation NZ has ...

A computational study shows for the first time how different parts of the human airway experience levels of pressure and ...

INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.

April 7 (Reuters) - Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial. The drug, ...

The DPP1 inhibitor did not beat placebo in this trial, leaving branded Bimzelx and Cosentyx, as well as Humira and its generics to reign across the HS market.

In the 2000s, when the AIDS pandemic hit South Africa, we were seeing a lot of children dying from HIV. That was just before ...

For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand ...

Insmed (INSM) stock is in focus as the company halts studies for lung disorder therapy brensocatib in hidradenitis ...

Billionaire investor Stanley Druckenmiller is known for making bold moves when conviction is high, and his latest portfolio ...

After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other ...

Insmed Incorporated (NASDAQ:INSM) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge ...

European data identify distinct multimorbidity patterns in severe asthma, linking comorbid clusters to outcomes, steroid use, ...